Prostate-specific membrane antigen (PSMA) expression in ovarian carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023240

Enrollment

100

Registered

2020-10-08

Start date

2020-10-10

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C56

Interventions

Group 1: Immunohistochemical evaluation of PSMA expression in tissue samples from malignant ovaries, which were stored in the biobank of the Comprehensive Cancer Center Freiburg Group 2: Immunohistoch

Eligibility

Sex/Gender

Female

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients with histopathologically confirmed, invasive serous ovarian carcinoma are included in this study.

Exclusion criteria

Exclusion criteria: missing declaration of consent other oncological disease Borderline tumor or other histological subtype (except the invasive serous ovarian carcinoma) Cytostatic therapy administered before the tissue sample is taken Radiotherapy performed before the tissue sample is taken

Design outcomes

Primary

Measure	Time frame
Description of the PSMA expression within the ovary and ovarian cancer	—

Secondary

Measure	Time frame
Depending on the PSMA status (both tumor cells and tumor novasculature): Survival Disease free survival (dfs) Clinical parameters: - Age at time of diagnosis, menopause status, FIGO stage at diagnosis time, distant metastasis, postoperative chemotherapy. Histopathological parameters: - pTNM stage, lymph node status (pelvic/paraaortal involvement) Grading (low or high grade).	—

Countries

Germany

Contacts

Public ContactPeter Bronsert

Universitätsklinikum FreiburgDepartement für klinische Pathologie

peter.bronsert@uniklinik-freiburg.de004976127080660

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026